ALK Introduces ODACTRA for house dust mite (HDM)-induced allergic rhinitis patients

Pharmaceutical company ALK introduction of its sublingual allergy immunotherapy (SLIT) tablet ODACTRA set to be rolled out for US Patients in the age group of 18- 65 years afflicted with house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis.

As per reports, rhinitis is inflicted on 50 million Americans. HDM is the most visible indoor allergen in the US with 84% of homes having detectable levels of the allergen.

According to Bradley Chipps, MD, practicing Allergist & Immunologist and current President of American College of Allergy, Asthma and Immunology, “The introduction of ODACTRA, a fast dissolving immunotherapy tablet for the treatment of dust mite allergy, provides another treatment option for physicians and patients.  Many patients find traditional immunotherapy, by shots, to be inconvenient.  ODACTRA, is an effective, once a day tablet that provides another option for those patients who could benefit from immunotherapy.”

ODACTRA is the first HDM SLIT-tablet to be approved for use in the US and its safety and efficacy were testified  in the world’s largest allergy immunotherapy clinical trial program, involving more than 6,000 patients. ODACTRA vouches to met out  a relevant treatment option that can reduce the symptoms of house dust mite induced allergic rhinitis. However, it is noteworthy that ODACTRA might inflict profound devastating allergic reactions including symptoms like breathing barriers, throat tightness or swelling, rapid or weak heartbeat thereby calling for doctor’s prescription to use the mentioned tablet in order to avert adverse consequences